http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100364938-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
filingDate | 1998-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2002-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2002-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-100364938-B1 |
titleOfInvention | Medicament containing interferon-alpha and amantadine for the treatment of chronic hepatitis c |
abstract | The present invention provides the use of IFN-α in combination with amantadine for the manufacture of a medicament for the treatment of chronic hepatitis C. The present invention also provides a medicament containing IFN-α and amantadine as a combined formulation for use simultaneously, separately or continuously in the treatment of chronic hepatitis C. The present invention provides chronic C treatment in patients in need of treatment of chronic hepatitis C, comprising administering an amount of IFN-α effective to treat hepatitis C with an amount of amantadine effective to treat hepatitis C. Additional methods are provided for treating hepatitis. |
priorityDate | 1997-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.